NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The NICE Centre for Clinical Practice is an NHS Evidence accredited provider 19 August 2011 New NICE guidance on the management of stable angina (clinical guideline [CG] 126) has […]
Category Archives: Cardiovascular disease
NPC Archive Item: A2RAs: no substantially increased risk of MI, but ACE inhibitors still first line
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28 June 2011 A large meta-analysis provides evidence that angiotensin-II receptor antagonists (A2RAs) do not substantially increase the risk of MI, all-cause or CV mortality, or angina, as was […]
NPC Archive Item: Olmesartan reduces disease oriented outcomes but may have potential cardiovascular safety concerns
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 28th March 2011 The ROADMAP trial found olmesartan delayed the onset of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. While this disease-oriented outcome (DOO) suggested a potential benefit […]
NPC Archive Item: More improvement needed in the drug management of heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 8th February 2011 The National Heart Failure audit 2010 confirms the improvements suggested last year in the use of key treatments for heart failure, such as ACE inhibitors and beta […]
NPC Archive Item: Does eplerenone▼ have a role in mild heart failure?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13th January 2011 The EMPHASIS-HF study found that adding eplerenone▼ to recommended therapy for heart failure (HF) with left ventricular systolic dysfunction (LVSD) reduced the risk of a composite […]
NPC Archive Item: New from NICE: Important changes in the use of clopidogrel and modified-release dipyridamole
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 17 May 2011 Clopidogrel* alone is now recommended by NICE with no limits on duration of treatment in people who have had an ischaemic stroke. Modified-release (MR) dipyridamole plus aspirin […]
NPC Archive Item: Reducing treatment dose errors with low molecular weight heparins
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 06 September 2010 Introduction In July 2010, the National Patient Safety Agency (NPSA) issued its Rapid Response Report: Reducing treatment dose errors with low molecular weight heparins (LMWHs)1, making […]
NPC Archive Item: May Drug Safety Update from MHRA/CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 26 May 2010 The MHRA and CHM have published the May edition of Drug Safety Update This edition includes […]
NPC Archive Item: What is the place in therapy of simvastatin 80mg in the light of recent MHRA guidance?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25 May 2010 The May edition of Drug Safety Update includes an article advising healthcare professionals that the product information for simvastatin has been updated to highlight the increased […]
NPC Archive Item: Do statins have mortality benefits in heart failure?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 14 May 2010 This meta-analysis found that while statins reduced hospitalisation for worsening heart failure, they did not significantly reduce all-cause mortality or cardiovascular mortality in people with heart […]